JPH0113469B2 - - Google Patents

Info

Publication number
JPH0113469B2
JPH0113469B2 JP55089128A JP8912880A JPH0113469B2 JP H0113469 B2 JPH0113469 B2 JP H0113469B2 JP 55089128 A JP55089128 A JP 55089128A JP 8912880 A JP8912880 A JP 8912880A JP H0113469 B2 JPH0113469 B2 JP H0113469B2
Authority
JP
Japan
Prior art keywords
methyl
thiomethyl
aminoethyl
imidazole
hydroxymethylimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP55089128A
Other languages
Japanese (ja)
Other versions
JPS5714576A (en
Inventor
Tomoyasu Tashiro
Saburo Uchikuga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sogo Pharmaceutical Co Ltd
Original Assignee
Sogo Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sogo Pharmaceutical Co Ltd filed Critical Sogo Pharmaceutical Co Ltd
Priority to JP8912880A priority Critical patent/JPS5714576A/en
Priority to GB8119385A priority patent/GB2079276B/en
Priority to DE19813125990 priority patent/DE3125990A1/en
Publication of JPS5714576A publication Critical patent/JPS5714576A/en
Publication of JPH0113469B2 publication Critical patent/JPH0113469B2/ja
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Description

【発明の詳細な説明】 本発明は、式(3) で示される4−メチル−5−〔(2−アミノエチ
ル)チオメチル〕イミダゾールを製造するための
新規にして有用な方法に関するものである。
[Detailed Description of the Invention] The present invention provides formula (3) The present invention relates to a new and useful method for producing 4-methyl-5-[(2-aminoethyl)thiomethyl]imidazole.

この式(3)で示されるイミダゾール誘導体は、式
(4) で示される重要な医薬品であるシメチジンの合成
中間体として使用できるという重要な用途を有す
る化合物である。式(4)で示されるシメチジンは、
ヒスタミンH2−受容体拮抗剤として有効な化合
物であつて、特に胃及び十二指腸潰瘍治療の分野
において非常に重要な医薬品である。
The imidazole derivative represented by this formula (3) has the formula
(Four) It is a compound that has important uses as it can be used as an intermediate for the synthesis of cimetidine, an important pharmaceutical product shown in Cimetidine represented by formula (4) is
It is a compound effective as a histamine H 2 -receptor antagonist, and is a very important drug, especially in the field of gastric and duodenal ulcer treatment.

本発明の目的化合物である4−メチル−5−
〔(2−アミノエチル)チオメチル〕イミダゾール
は従来4−メチル−5−ヒドロキシメチルイミダ
ゾールとシステアミンとを反応させる方法が専ら
行われてきたが(特開昭47−42661)、4−メチル
−5−ヒドロキシメチルイミダゾールと2−アミ
ノエタンチオール硫酸から合成する方法も最近に
なつて開発されている(特開昭55−87773号)。
4-methyl-5- which is the object compound of the present invention
[(2-Aminoethyl)thiomethyl]imidazole has conventionally been produced by reacting 4-methyl-5-hydroxymethylimidazole with cysteamine (Japanese Patent Application Laid-Open No. 47-42661), but 4-methyl-5- A method for synthesizing it from hydroxymethylimidazole and 2-aminoethanethiol sulfuric acid has also been recently developed (Japanese Patent Application Laid-open No. 87773/1983).

しかしながら前者のシステアミンは、空気酸化
を受けやすく、副生成物の混入、収率の低下は避
けられない。また後者については、非常に厄介な
副生する硫酸の分離を必らず行わねばならないと
いう大きな欠点を有する。
However, the former cysteamine is susceptible to air oxidation, and contamination with by-products and a decrease in yield are unavoidable. The latter method also has a major drawback in that it requires the very troublesome separation of sulfuric acid as a by-product.

本発明は、両者の持つ大きな欠点を取り除くた
めになされたものであり、システアミン、2−ア
ミノエタンチオール硫酸に代わる好適な原料を求
めて研究を重ねた結果、式(2)で示される2,2−
2置換チアゾリジンが好適であることをつきと
め、完成されたものである。すなわち、本発明
は、次の反応式で示される4−メチル−5−〔(2
−アミノエチル)チオメチル〕イミダゾールの製
造方法である。
The present invention was made to eliminate the major drawbacks of both cysteamine and 2-aminoethanethiol sulfuric acid, and as a result of repeated research in search of a suitable raw material to replace cysteamine and 2-aminoethanethiol sulfuric acid, 2, 2-
It was discovered that 2-substituted thiazolidine was suitable and was completed. That is, the present invention provides 4-methyl-5-[(2
-aminoethyl)thiomethyl]imidazole.

(式中、R1、R2はそれぞれアルキル基若しくは
フエニル基を表わし、又はR1、R2は一緒になつ
て環を形成する。) 本発明における原料化合物である2,2−2置
換チアゾリジンは、そのイオウ原子がチオエーテ
ル結合を形成しているため、空気酸化を受けにく
い物質であるし、また反応によつて副生するケト
ンは、減圧濃縮によつて容易に除去することがで
きる。また、最近になつて、2,2−2置換チア
ゾリジンは、モノエタノールアミンの硫酸エステ
ルと、ケトン、水硫化物から、安価に製造するこ
とも開発され(特開昭56−81574)原料化合物と
しては非常に有利である。さらに、この2,2−
2置換チアゾリジンを加水分解することによつ
て、従来の合成原料であつたシステアミンを容易
に製造することができることも判明した(特開昭
56−8358号)。
(In the formula, R 1 and R 2 each represent an alkyl group or a phenyl group, or R 1 and R 2 are taken together to form a ring.) 2,2-2-substituted thiazolidine which is a raw material compound in the present invention Because its sulfur atoms form a thioether bond, it is a substance that is not susceptible to air oxidation, and the ketone produced by the reaction can be easily removed by vacuum concentration. In addition, recently, it has been developed that 2,2-disubstituted thiazolidine can be produced inexpensively from monoethanolamine sulfate, ketone, and hydrosulfide (Japanese Patent Application Laid-open No. 81574/1983) as a raw material compound. is very advantageous. Furthermore, this 2,2-
It was also found that cysteamine, which was a conventional synthetic raw material, could be easily produced by hydrolyzing disubstituted thiazolidine (Japanese Patent Application Laid-open No.
56-8358).

これに対して本発明方法は、システアミンの合
成原料である2,2−2置換チアゾリジンを使用
するにもかかわらず、加水分解工程を取り除くこ
とを可能にしたわけであつて、その効果は、一工
程削減による効率向上にとどまらず、収率、品質
の上昇につながり、非常に顕著なものが得られ
る。本発明方法を採用することによつて、前記し
た従来法の有する欠点がすべて解決されることは
いうまでもない。
In contrast, the method of the present invention makes it possible to eliminate the hydrolysis step even though it uses 2,2-2-substituted thiazolidine, which is a raw material for cysteamine synthesis, and the effect is that it is possible to eliminate the hydrolysis step in one step. Not only does the reduction improve efficiency, but it also leads to an increase in yield and quality, which is very noticeable. It goes without saying that by employing the method of the present invention, all of the drawbacks of the conventional methods described above are solved.

本発明における2,2−2置換チアゾリジンと
4−メチル−5−ヒドロキシメチルイミダゾール
の反応は、水の存在しない氷酢酸中でも十分に進
行するという新規な知見が得られたが、これによ
れば、2,2−2置換チアゾリジンは、4−メチ
ル−5−ヒドロキシメチルイミダゾールと反応を
起こした結果、開環するということになり、本発
明に係る反応はまつたく新規な化学反応であると
いい得るのである。
A novel finding was obtained that the reaction between 2,2-2-substituted thiazolidine and 4-methyl-5-hydroxymethylimidazole in the present invention proceeds satisfactorily even in glacial acetic acid in the absence of water. 2,2-2-substituted thiazolidine undergoes ring opening as a result of reaction with 4-methyl-5-hydroxymethylimidazole, and the reaction according to the present invention can be said to be a completely new chemical reaction. It is.

すなわち本発明に係る反応は、加水分解反応で
はない点で非常に特異的であり、前記した2,2
−2置換チアゾリジンからシステアミンを経由し
てイミダゾールと反応させる方法とは根本的に異
なるものである。
In other words, the reaction according to the present invention is very specific in that it is not a hydrolysis reaction, and is
This method is fundamentally different from the method in which a -2-substituted thiazolidine is reacted with imidazole via cysteamine.

本発明方法では、4−メチル−5−ヒドロキシ
メチルイミダゾールは塩の形、例えば鉱酸塩、あ
るいは遊離塩基で、遊離塩基又は例えば鉱酸塩と
いつた塩の形にした2,2−2置換チアゾリジン
と反応させることができる。
In the process of the invention, 4-methyl-5-hydroxymethylimidazole is used in the form of a salt, e.g. a mineral acid salt, or in a free base, with a 2,2-2 substituted Can be reacted with thiazolidine.

2,2−2置換チアゾリジンとしては、2,2
−ジメチルチアゾリジン、2−メチル−2−エチ
ルチアゾリジン、2−メチル−2−イソブチルチ
アゾリジン、スピロシクロヘキサン−1,2′−チ
アゾリジン、2−メチル−2−フエニルチアゾリ
ジンなどが広く使用されるが、特に好ましくは、
2,2−ジメチルチアゾリジン、2−メチル−2
−エチルチアゾリジンである。
As the 2,2-2-substituted thiazolidine, 2,2
-Dimethylthiazolidine, 2-methyl-2-ethylthiazolidine, 2-methyl-2-isobutylthiazolidine, spirocyclohexane-1,2'-thiazolidine, 2-methyl-2-phenylthiazolidine, etc. are widely used, but especially Preferably,
2,2-dimethylthiazolidine, 2-methyl-2
-Ethylthiazolidine.

溶媒としては一般に有機合成において使用され
る酸性溶媒が使用できるが、特に好ましくは、酢
酸、又はハロゲン化水素酸である。
As the solvent, acidic solvents commonly used in organic synthesis can be used, but acetic acid or hydrohalic acid is particularly preferred.

反応時間は、条件によつても異なるが、通常、
1〜10時間であり、反応終了後、減圧濃縮乾固
し、イソプロピルアルコールまたは、アセトンに
分散、冷却、過すると、白色結晶の4−メチル
−5−〔(2−アミノエチル)チオメチル〕イミダ
ゾール・2ハロゲン酸塩が得られる。
The reaction time varies depending on the conditions, but usually
After the reaction is completed, it is concentrated to dryness under reduced pressure, dispersed in isopropyl alcohol or acetone, cooled, and filtered to give white crystals of 4-methyl-5-[(2-aminoethyl)thiomethyl]imidazole. A dihalogen salt is obtained.

次に本発明の実施例とシメチジン合成の参考例
を示す。
Next, examples of the present invention and reference examples of cimetidine synthesis will be shown.

実施例 1 酢酸25c.c.に4−メチル−5−ヒドロキシメチル
イミダゾール塩酸塩4.5gと2,2−ジメチルチ
アゾリジン塩酸塩4.6gを加え、還流下2時間反
応させ、減圧下で酢酸を除去した後、イソプロピ
ルアルコール50c.c.を加えて、分散、冷却、過、
乾燥すると、白色結晶の4−メチル−5−〔(2−
アミノエチル)チオメチル〕イミダゾール・2塩
酸塩5.9g(収率81.2%)が得られる。薄層クロ
マトグラフイーとI.Rで標準品と一致した。
Example 1 4.5 g of 4-methyl-5-hydroxymethylimidazole hydrochloride and 4.6 g of 2,2-dimethylthiazolidine hydrochloride were added to 25 c.c. of acetic acid, reacted under reflux for 2 hours, and acetic acid was removed under reduced pressure. After that, add 50 c.c. of isopropyl alcohol, disperse, cool, filter,
When dried, white crystals of 4-methyl-5-[(2-
5.9 g (yield: 81.2%) of (aminoethyl)thiomethyl]imidazole dihydrochloride is obtained. Thin layer chromatography and IR results matched the standard product.

実施例 2 酢酸25c.c.に4−メチル−5−ヒドロキシメチル
イミダゾール塩酸塩4.5gと、2−メチル−2−
エチルチアゾリジン塩酸塩5.0gを加え、還流下
2時間反応させ、減圧下で酢酸を除去した後、イ
ソプロピルアルコール50c.c.を加えて、分散、冷
却、過、乾燥すると、白色結晶の4−メチル−
5−〔(2−アミノエチル)チオメチル〕イミダゾ
ール・2塩酸塩5.9g(収率81.2%)が得られる。
Example 2 4.5 g of 4-methyl-5-hydroxymethylimidazole hydrochloride and 2-methyl-2-
Add 5.0 g of ethylthiazolidine hydrochloride, react under reflux for 2 hours, remove acetic acid under reduced pressure, add 50 c.c. of isopropyl alcohol, disperse, cool, filter, and dry. 4-methyl −
5.9 g (yield: 81.2%) of 5-[(2-aminoethyl)thiomethyl]imidazole dihydrochloride is obtained.

薄層クロマトグラフイーとI.Rで標準品と一致
した。
Thin layer chromatography and IR results matched the standard product.

実施例 3 濃塩酸80c.c.に4−メチル−5−ヒドロキシメチ
ルイミダゾール塩酸塩4.5gと2−メチル−2−
イソブチルチアゾリジン塩酸塩5.9gを加え、還
流下2時間反応させた後、減圧下で十分に水を除
去し、イソプロピルアルコール50c.c.を加え、分
散、冷却、過、乾燥すると、白色結晶の4−メ
チル−5〔(2−アミノエチル)チオメチル〕イミ
ダゾール・2塩酸塩4.7g(収率64.8%)が得ら
れる。
Example 3 4.5 g of 4-methyl-5-hydroxymethylimidazole hydrochloride and 2-methyl-2- in 80 c.c. of concentrated hydrochloric acid
After adding 5.9 g of isobutylthiazolidine hydrochloride and reacting under reflux for 2 hours, water was thoroughly removed under reduced pressure, and 50 c.c. of isopropyl alcohol was added, dispersed, cooled, filtered, and dried to form white crystals. -Methyl-5[(2-aminoethyl)thiomethyl]imidazole dihydrochloride 4.7g (yield 64.8%) is obtained.

薄層クロマトグラフイーとI.Rで標準品と一致
した。
Thin layer chromatography and IR results matched the standard product.

実施例 4 48%臭化水素酸60c.c.に、4−メチル−5−ヒド
ロキシメチルイミダゾール塩酸塩4.5gとスピロ
シクロヘキサン−1,2′−チアゾリジン塩酸塩
5.8gを加え、還流下2時間反応させた後、減圧
下で十分に水分を除去し、アセトン50c.c.を加え、
分散、冷却、過、乾燥すると、白色結晶の4−
メチル−5−〔(2−アミノエチル)チオメチル〕
イミダゾール・2塩酸塩5.4g(収率74.4%)が
得られる。薄層クロマトグラフイーとI.Rが標準
品と一致した。
Example 4 4.5 g of 4-methyl-5-hydroxymethylimidazole hydrochloride and spirocyclohexane-1,2'-thiazolidine hydrochloride in 60 c.c. of 48% hydrobromic acid.
After adding 5.8 g and reacting under reflux for 2 hours, water was thoroughly removed under reduced pressure, and 50 c.c. of acetone was added.
When dispersed, cooled, filtered and dried, white crystals of 4-
Methyl-5-[(2-aminoethyl)thiomethyl]
5.4 g (yield 74.4%) of imidazole dihydrochloride is obtained. Thin layer chromatography and IR were consistent with the standard product.

実施例 5 濃塩酸80c.c.に、4−メチル−5−ヒドロキシメ
チルイミダゾール塩酸塩4.5gと2−メチル−2
−フエニルチアゾリジン5.4gを加え、還流下2
時間反応させた後、減圧下で十分に水分を除去
し、アセトン50c.c.を加え、分散、冷却、過、乾
燥すると、白色結晶の4−メチル−5−〔(2−ア
ミノエチル)チオメチル〕イミダゾール・2塩酸
塩4.7g(収率64.8%)が得られる。
Example 5 In 80 c.c. of concentrated hydrochloric acid, 4.5 g of 4-methyl-5-hydroxymethylimidazole hydrochloride and 2-methyl-2
- Add 5.4 g of phenylthiazolidine and reflux for 2 hours.
After reacting for an hour, water was thoroughly removed under reduced pressure, 50 c.c. of acetone was added, dispersed, cooled, filtered, and dried, resulting in white crystals of 4-methyl-5-[(2-aminoethyl)thiomethyl ] 4.7 g (yield 64.8%) of imidazole dihydrochloride is obtained.

薄層クロマトグラフイーとI.Rが標準品と一致
した。
Thin layer chromatography and IR were consistent with the standard product.

実施例 6 4−メチル−5−〔(2−アミノエチル)チオメ
チル〕イミダゾール 酢酸30c.c.に、2−メチル−2−エチルチアゾリ
ジン塩酸塩4.6gを加える。これに、4−メチル
−5−ヒドロキシメチルイミダゾール塩酸塩4.5
gを加え、還流下10時間反応させ、減圧下で酢酸
を除去した後、イソプロピルアルコール50c.c.を加
えて分散、冷却、過、乾燥すると、白色結晶の
4−メチル−5−〔(2−アミノエチル)チオメチ
ル〕イミダゾール・2塩酸塩7.0g(収率95.9%)
が得られる。
Example 6 4-Methyl-5-[(2-aminoethyl)thiomethyl]imidazole To 30 c.c. of acetic acid is added 4.6 g of 2-methyl-2-ethylthiazolidine hydrochloride. To this, 4-methyl-5-hydroxymethylimidazole hydrochloride 4.5
After adding 10 g of 4-methyl-5- -aminoethyl)thiomethyl]imidazole dihydrochloride 7.0g (yield 95.9%)
is obtained.

薄層クロマトグラフイーとI.Rが標準品と一致
した。
Thin layer chromatography and IR were consistent with the standard product.

参考例 N−シアノ−N′−〔2−((4−メチル−5−イ
ミダゾリル)メチルチオ)エチル〕−O−エチ
ルイソ尿素 実施例6で得た4−メチル−5−〔(2−アミノ
エチル)チオメチル〕イミダゾール・2塩酸塩
4.9gに水40c.c.、炭酸カリウム2.8g、O−エチル
−5−メチルシアノチオイミドカルボネート2.9
gとエタノール40c.c.の溶液を加え、60℃で2時間
反応させ、減圧下でエタノールを除去し、冷却、
過、乾燥すると、白色結晶のN−シアノ−
N′−〔2−((4−メチル−5−イミダゾリル)メ
チルチオ)エチル〕−O−エチルイソ尿素、4.8g
(収率89.7%)が得られる。
Reference example N-cyano-N'-[2-((4-methyl-5-imidazolyl)methylthio)ethyl]-O-ethylisourea 4-Methyl-5-[(2-aminoethyl) obtained in Example 6 Thiomethyl imidazole dihydrochloride
4.9g, 40c.c. of water, 2.8g of potassium carbonate, 2.9g of O-ethyl-5-methylcyanothioimide carbonate
Add a solution of g and 40 c.c. of ethanol, react at 60°C for 2 hours, remove ethanol under reduced pressure, cool,
When filtered and dried, white crystals of N-cyano-
N'-[2-((4-methyl-5-imidazolyl)methylthio)ethyl]-O-ethyl isourea, 4.8 g
(Yield 89.7%) is obtained.

薄層クロマトグラフイーとI.Rが標準品と一致
した。
Thin layer chromatography and IR were consistent with the standard product.

N−シアノ−N′−メチル−N″−〔2−((4−メ
チル−5−イミダゾリル)メチルチオ)エチ
ル〕グアニジン(シメチジン) 上で得たN−シアノ−N′−〔2−((4−メチル
−5−イミダゾリル)メチルチオ)エチル〕−O
−エチルイソ尿素4.0gに、エタノール45c.c.、水
45c.c.、氷冷下5℃以下でモノメチルアミン40%水
溶液56c.c.を加え、冷却したままで一夜撹拌し、減
圧濃縮乾固の後、アセトニトリル20c.c.を加えて、
冷却、過、乾燥すると、白色結晶のシメチジ
ン、すなわちN−シアノ−N′−メチル−N″−〔2
−((4−メチル−5−イミダゾリル)メチルチ
オ)エチル〕グアニジン3.0g(収率78.9%)が
得られる。
N-cyano-N'-methyl-N''-[2-((4-methyl-5-imidazolyl)methylthio)ethyl]guanidine (cimetidine) N-cyano-N'-[2-((4 -Methyl-5-imidazolyl)methylthio)ethyl]-O
-4.0 g of ethyl isourea, 45 c.c. of ethanol, and water
45 c.c., add 56 c.c. of a 40% monomethylamine aqueous solution at below 5°C under ice-cooling, stir overnight while cooling, concentrate to dryness under reduced pressure, and then add 20 c.c. of acetonitrile.
Upon cooling, filtering and drying, white crystalline cimetidine, N-cyano-N'-methyl-N''-[2
3.0 g (yield 78.9%) of -((4-methyl-5-imidazolyl)methylthio)ethyl]guanidine is obtained.

薄層クロマトグラフイーとI.Rが標準品と一致
した。
Thin layer chromatography and IR were consistent with the standard product.

Claims (1)

【特許請求の範囲】 1 式(1) で示される4−メチル−5−ヒドロキシメチルイ
ミダゾールに 式(2) (式中、R1、R2はそれぞれアルキル基、若しく
はフエニル基を表わし、又はR1、R2は一緒にな
つて環を形成する。) で示される2,2−2置換チアゾリジンを反応さ
せることを特徴とする式(3) で示される4−メチル−5−〔(2−アミノエチ
ル)チオメチル〕イミダゾールの製造方法。
[Claims] 1 Formula (1) For 4-methyl-5-hydroxymethylimidazole represented by formula (2) (In the formula, R 1 and R 2 each represent an alkyl group or a phenyl group, or R 1 and R 2 are taken together to form a ring.) A 2,2-2-substituted thiazolidine represented by Equation (3) is characterized by A method for producing 4-methyl-5-[(2-aminoethyl)thiomethyl]imidazole.
JP8912880A 1980-07-02 1980-07-02 Preparation of imidazole derivative Granted JPS5714576A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP8912880A JPS5714576A (en) 1980-07-02 1980-07-02 Preparation of imidazole derivative
GB8119385A GB2079276B (en) 1980-07-02 1981-06-23 4-methyl-5-((2-aminoethyl)thiomethyl)imidazole production
DE19813125990 DE3125990A1 (en) 1980-07-02 1981-07-01 Process for preparing imidazole derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8912880A JPS5714576A (en) 1980-07-02 1980-07-02 Preparation of imidazole derivative

Publications (2)

Publication Number Publication Date
JPS5714576A JPS5714576A (en) 1982-01-25
JPH0113469B2 true JPH0113469B2 (en) 1989-03-06

Family

ID=13962240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8912880A Granted JPS5714576A (en) 1980-07-02 1980-07-02 Preparation of imidazole derivative

Country Status (3)

Country Link
JP (1) JPS5714576A (en)
DE (1) DE3125990A1 (en)
GB (1) GB2079276B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8361782A (en) * 1981-05-26 1982-12-02 Bridge Chemicals Ltd. Preparation of 4-(2-aminoethylthiomethyl)-5-methylimidazole
JPS6090857U (en) * 1983-11-29 1985-06-21 株式会社ミニパイロ電機 LED lamp
JPS62178237U (en) * 1986-05-02 1987-11-12
JPH01272570A (en) * 1988-04-26 1989-10-31 Nippon Shokubai Kagaku Kogyo Co Ltd Production of 4-methyl-5-((2-aminoethyl)-thiomethyl)-imidazole

Also Published As

Publication number Publication date
GB2079276A (en) 1982-01-20
JPS5714576A (en) 1982-01-25
DE3125990A1 (en) 1982-02-04
GB2079276B (en) 1984-07-25

Similar Documents

Publication Publication Date Title
US4013678A (en) Process for preparing heterocyclicalkylthioalkyl-n-cyanoguanidines
JPH0339061B2 (en)
JPH01172378A (en) Novel 2-guanidine-thiazole compound, its production and use thereof as intermediate of phamotidine method
SU677655A3 (en) Method of producing n-cyclo-alkymethyl-2-phenylamino-imidazolines-2- or salts thereof
JPH0113469B2 (en)
WO1998029394A1 (en) Process for the preparation of carbamoyllated imidazole derivatives
HU211774B (en) Improved process for the synthesis of n-[3-(1h-imidazol-1-yl)phenyl]-4-substituted-2-pyrimidinamines
HU196212B (en) Process of dividing of 7-/d-2-amin-2-/4-hydroxi-phenyl/-acetamid-1-/propenyl/-cef-3-em-4-carbonic acid and its /e/-izomer
SU420176A3 (en)
HU185457B (en) Process for preparating cimetidine-z
CS220346B2 (en) Method of preparing crystalline cimetidine
US4855439A (en) Process for the preparation of cimetidine
US4090026A (en) Certain nitrogen heterocyclic isothiocyanate esters
KR900006556B1 (en) Process for preparing 2-guanidinothiazole derivatives
JPS6144867B2 (en)
JPS636063B2 (en)
AT397087B (en) Process for the preparation of 3-(((2- ((diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N- sulphamoylpropionamidine, novel intermediates which can be used in this process, and a process for the preparation of novel intermediates.
NO774407L (en) PROCEDURE FOR PREPARING IMIDAZOLE DERIVATIVES
HU185298B (en) Process for producing cimetidine
KR870001794B1 (en) Process for preparing guanidino thiazole compounds
RU2042671C1 (en) Diketoneimine derivative as an intermediate product for synthesis of ranitidine and method of its synthesis
JPS6272680A (en) Manufacture of ranitidine or acid addition salt of same
KR870001157B1 (en) Process for the preparation of guanidinothiazole compounds
JPS63192747A (en) Formate of formamidine
JPH0379345B2 (en)